SRD Pharmaceuticals Acquires Drug Patents For New Treatment Of AIDS; Will Apply To Utilize FDA's "Fast Track" System To Expedite Marketing Approval
10/19/2005 5:11:10 PM
SRD Pharmaceuticals, Inc. today announced it has acquired 4 U.S. patents, 16 corresponding foreign patents and 4 additional patents pending from Nissin Foods, Ltd. of Japan. The acquisition includes the associated technologies and FDA filings related to an AIDS drug developed by Nissin's Molecular Biology Institute. Nissin spent 10 years and 17 million dollars to create this drug for the treatment of AIDS, based on "humanized" monoclonal antibody (MAb) technology. The drug binds to the HIV virus and leads to the activation of a part of the immune system that disrupts the virus.